Drug Profile
Research programme: monoclonal antibody biosimilars - PharmaPraxis/PlantForm Corporation
Alternative Names: Bevacizumab biosimilarLatest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator PlantForm - PharmaPraxis (JV)
- Class Monoclonal antibodies
- Mechanism of Action Angiogenesis inhibitors; Immunomodulators; Vascular endothelial growth factor A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer; Immunological disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in Brazil (Parenteral)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Immunological-disorders in Brazil (Parenteral)
- 20 Jun 2014 PharmaPraxis and PlantForm establish a joint venture to develop biosimilar monoclonal antibodies in Brazil for the treatment of cancer and immunological disorders